CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Jeremy Levin

Executive Chairman, Ovid Therapeutics

Search every verified Jeremy Levin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jeremy Levin, executive chairman of Ovid Therapeutics and former CEO of Teva Pharmaceutical Industries, has been promoting his forthcoming book, "Biotech and the Balance," scheduled for publication on May 19, 2026. In recent podcast appearances, he has discussed the state of the biotechnology sector, arguing that the U.S. should treat biotech as a strategic national asset and that current capital markets are poorly suited to funding early-stage innovation. He has stated that the traditional venture capital funding model—seed, A, B, C rounds followed by an IPO—is largely unavailable to many founders, and he has pointed to pooled family offices, grant money, and collaborations with patient advocacy groups as alternative funding sources. Levin has also expressed concerns about the long-term competitiveness of the U.S. biotech industry, saying that the damage from current policy approaches can be repaired but that the country may not retain its global dominance. He has described the impact of drug pricing measures as having a "trickle-down" effect on small biotech companies, which rely on stock prices to fund research. He has called for entrepreneurs to "be fearless" and to think beyond traditional funding pathways, while also warning that other countries are advancing in biotech innovation.

Recent appearances

Verified interview transcripts

Notable quotes

“The funding crisis is not measured only by dollars raised. Frankly, it's measured by the quality and the number of really great scientific ideas that never got tested. That is the true test. Who would imagine that Genentech would have gone into fund the programs it did if it didn't have an incredible group of leaders? Who would imagine that you wouldn't that you wouldn't have the types of risk taken in Alnylam who to”

“The past few years have really altered my thinking from concern and involvement with things like bio trying to deal with those concerns to real urgency. I used to think the biotech system was simply under day-to-day strain that things would continue but we could actually fix them. But then several things hit me really clearly and it started some years ago. Number one was the clear recognition that pharma and biotech ”

“The damage being done now can be repaired. Like it will be repaired. However, what emerges is that we will not keep our continuity and growth. And so, others aren't standing still. They're not waiting for us. When we emerge from this miasma, this tremendously poorly thought through approach to this industry, we will find that we will not be the world dominant and perhaps we shouldn't be. But we will be facing competi”

“Let's step back cuz each one of these is in my opinion tactical. The question here is not is China a force in biotech. The question is when will it become the dominant force. And it's occurring for several very clear reasons that I hear repeatedly from people in the industry. But let me start by saying there's no clear direct link with what goes on in Iran. In the minds of those, or at least the way they are articula”

“If we ask the question, where is the next great cancer drug going to be invented? Where is the next great Alzheimer's drug going to be invented? Where is the cure for baldness going to be invented? The answer is it should be here. But we can't stop somebody else doing it. We just need to do it better. And we can. Look at the extraordinary things that we've invented in this country. Extraordinary things. Where'd the e”

“The trickle-down is immediate, consequential, because remember what I said about these small companies. They live by their stock price. When an imposition is made on the pharmaceutical companies, there is an immediate market reaction. The stock price of these companies plummet, and they sell their stock to fund the innovation. The cost of their money goes huge, becomes enormous. They can't afford to develop new drugs”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →